AstraZeneca PLC
27 July 2005
AstraZeneca second quarter and half year results 2005
Tomorrow, Thursday, 28 July 2005 AstraZeneca will be releasing its second
quarter and half year results for 2005 at 11:00bst.
An analysts' presentation of the second quarter and half year results will take
place at 13:00bst. You will be able to access the presentation via two routes:
1) Audio webcast (available at www.astrazeneca.com). You will be able to email
questions to the presenters during the Q&A session. If you wish to take part in
the Q&A session live rather than by e-mail you will need to dial in to the
teleconference, details below.
2) Teleconference for which the numbers are in the UK: 0800 279 9640,
International: +44 (0)20 7784 1004 and for the US: 866 850 2201. Printable .pdf
versions (b/w) of slides will be available to download on the AstraZeneca
Investor Relations website (www.astrazeneca.com/node/investor.aspx) 15 minutes
before the analysts presentation begins.
Details of the teleconference and webcast replay facilities available until
Monday, 8 August are available on the Investor Relations part of the AstraZeneca
website at www.astrazeneca.com.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.